BMS-754807

Catalog No.S1124

BMS-754807 Chemical Structure

Molecular Weight(MW): 461.49

BMS-754807 is a potent and reversible inhibitor of IGF-1R/InsR with IC50 of 1.8 nM/1.7 nM in cell-free assays, less potent to Met, Aurora A/B, TrkA/B and Ron, and shows little activity to Flt3, Lck, MK2, PKA, PKC etc. Phase 2.

Size Price Stock Quantity  
USD 180 In stock
USD 270 In stock
USD 770 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Purity & Quality Control

Choose Selective IGF-1R Inhibitors

Biological Activity

Description BMS-754807 is a potent and reversible inhibitor of IGF-1R/InsR with IC50 of 1.8 nM/1.7 nM in cell-free assays, less potent to Met, Aurora A/B, TrkA/B and Ron, and shows little activity to Flt3, Lck, MK2, PKA, PKC etc. Phase 2.
Features Muti-inhibitor of the IGR-1R/IR family.
Targets
Insulin Receptor [1]
(Cell-free assay)
IGF-1R [1]
(Cell-free assay)
TrkB [1]
(Cell-free assay)
Met [1]
(Cell-free assay)
TrkA [1]
(Cell-free assay)
1.7 nM 1.8 nM 4.1 nM 5.6 nM 7.4 nM
In vitro

BMS-754807 effectively inhibits the growth of a broad range of human tumor cell lines of different histologic origins including mesenchymal (Ewing's, rhabdomyosarcoma, neuroblastoma, and liposarcoma), epithelial (breast, lung, pancreatic, colon, and gastric), and hematopoietic (multiple myeloma and leukemia), the IC50 values range from 5 nM to 365 nM for the most sensitive cell lines. BMS-754807 inhibits proliferation of IGF-1R-Sal cells and RH41 cells with IC50 of 7 nM and 5 nM. BMS-754807 inhibits phosphorylation of IGF-1R in IGF-1R-Sal cells, Rh41 and Geo with IC50 of 13 nM, 6 nM and 21 nM. BMS-754807 inhibits phosphorylation of Akt in IGF-1R-Sal cells, Rh41 and Geo with IC50 of 22 nM, 13 nM and 16 nM. BMS-754807 induces greater apoptosis in Rh41 cells by 24 hours as indicated by an increased sub-G1 peak (23.1%), compared with control (2.4%). [1] BMS-754807 inhibits the phosphorylation of IGF-1R (IC50 = 13nM) and the downstream targets Akt (IC50 = 22nM) and MAPK (IC50 = 13nM) in the IGF-Sal cell line with IC50 consistent with the antiproliferative IC50 (7 nM) in this cell line. The crystal structure of BMS-754807 cocrystallized with the kinase domain of IGF-1R shows that the donor/acceptor/donor hydrogen bond triad with Met1052 and Glu1050 within the hinge region of the kinase. [2] BMS-754807 shows a median EC50 value of 0.62 μM against 23 cell lines in the pediatric preclinical testing program (PPTP). [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
IGF-Sal NEKySpFMcW6jc3WgZZN{[Xl? Mk\RbY5pcWKrdIOgeIhmKHCqb4PwbI9zgWyjdHnvckBw\iCLR1[tNXIhMEmFNUCgQUAyO26PKTDhcoQhfGinIHTve45{fHKnYX2geIFz\2W2czDBb5QhMEmFNUCgQUAzOm6PKTDhcoQhVUGSSzCoTWM2OCB;IEGzcm0q MXKxPVc4QDB{NB?=
IGF-Sal M2rHfWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MU\JR|UxRTdibl2= NHTLVGYyQTd5OECyOC=>
CCRF-CEM (ALL) NW\xRpZoT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M17RNZ42KM7:TR?= MWLEUXNQ NX6ybIRDUUN3ME2xMlI{QSEQvF2= NH;JN3UyQTl7NkK3Ni=>
PC3 MW\Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NV7pO3dmhjVizszN Mn3oSG1UVw>? M4j1bGlEPTB;MD65OlUh|ryP NELud2oyQTl7NkK3Ni=>
JD NV;vb4YyT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M3\ZR542KM7:TR?= M4TPOWROW09? M1;JO2lEPTB;MD6zPVEh|ryP MlHpNVk6QTZ{N{K=
DU145 M1LSRWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NEfu[ot,PSEQvF2= MkLWSG1UVw>? MUfJR|UxRTFwNE[1JO69VQ>? NWLQTXp5OTl7OU[yO|I>
KAG NVX0eVBkT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MXr+OUDPxE1? M4PGPGROW09? NWjDflBDUUN3ME2xMlY3PSEQvF2= NUnrSWdbOTl7OU[yO|I>
K-562 (CML) NW\3N41kT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M1m5R542KM7:TR?= NEKze|ZFVVOR MUPJR|UxRTJwM{CyJO69VQ>? NGjFUoUyQTl7NkK3Ni=>
B6-P210 (Murine ALL) NHXlb3pIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NGDoZnN,PSEQvF2= MoPISG1UVw>? MXPJR|UxRTFwMkmzJO69VQ>? MnPuNVk6QTZ{N{K=
LN CAP-FGC NX7GVmZLT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NEXJe5Z,PSEQvF2= NXHTNXljTE2VTx?= MnzDTWM2OD1zLkSzOEDPxE1? NVizTYk{OTl7OU[yO|I>
VW MW\Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M2rvd542KM7:TR?= Mor5SG1UVw>? NEDNdW5KSzVyPUCuNFE6KM7:TR?= MWWxPVk6PjJ5Mh?=
MV411 (B Myelomonocytic) NYDjPYVqT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NYLUTFA3hjVizszN MVnEUXNQ M3r4emlEPTB;MD6zN{DPxE1? NGnt[osyQTl7NkK3Ni=>
MDA-PCa-2b NH7GOIVIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NWnCUHdshjVizszN MYXEUXNQ M4DORWlEPTB;MD6wPVgh|ryP NFH6[VkyQTl7NkK3Ni=>
LG NVq4W2x7T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MmT0glUh|ryP NXXWcmg2TE2VTx?= NWn0TWhGUUN3ME2wMlA{QCEQvF2= NEOyZ3UyQTl7NkK3Ni=>
RS411 (B cell precursor-ALL) MWTHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NH3lN3B,PSEQvF2= NX34d3R6TE2VTx?= NXnuOGplUUN3ME2wMlExOiEQvF2= M{f0S|E6QTl4Mkey
22-r-1 M1naVGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MoDJglUh|ryP M{T3eWROW09? NV3PNWdQUUN3ME2wMlE4PSEQvF2= MofqNVk6QTZ{N{K=
5838 M13UfWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NWPMU3VthjVizszN MoPkSG1UVw>? NHj4XoNKSzVyPUCuNFM1KM7:TR?= M37VdlE6QTl4Mkey
P388 (Murine) MXTHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NX\obHZZhjVizszN Ml\BSG1UVw>? MlnETWM2OD12LkK3JO69VQ>? M2nOSVE6QTl4Mkey
A2780/S NH\rOoFIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M{W1O542KM7:TR?= NELBVXhFVVOR NELSb4FKSzVyPUCuNVIzKM7:TR?= M3SwUVE6QTl4Mkey
RDES Mo\GS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NHPDZZl,PSEQvF2= MlvCSG1UVw>? NFzCc2VKSzVyPUCuNFEzKM7:TR?= NEHSTnoyQTl7NkK3Ni=>
B6-T315I (Murine B-ALL) NGPqfo9Iem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M3nIRZ42KM7:TR?= Ml63SG1UVw>? M3\DcmlEPTB;Mj64N{DPxE1? NVrlV3dQOTl7OU[yO|I>
TOV 112D M3rENGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 Ml2wglUh|ryP M2X3UGROW09? MlXHTWM2OD1{LkG0OkDPxE1? NYrPXVhtOTl7OU[yO|I>
TC32 NUfkVWFjT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NEmxcFl,PSEQvF2= MnLESG1UVw>? MUjJR|UxRTBwMEC4JO69VQ>? MUexPVk6PjJ5Mh?=
HL60 (acute myelocytic) MYDHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MVr+OUDPxE1? NYT1SIhGTE2VTx?= Mm\6TWM2OD1yLkGyJO69VQ>? NI\DNpUyQTl7NkK3Ni=>
TOV 21G NV\SdZU5T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NH;SO3F,PSEQvF2= MoLSSG1UVw>? NILKbXdKSzVyPUSuNlc6KM7:TR?= Mk\ENVk6QTZ{N{K=
TC71 MkXRS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? M1jaeJ42KM7:TR?= NIXEOFBFVVOR MojQTWM2OD1yLkCxOEDPxE1? M1f3RVE6QTl4Mkey
HPN-ALL (T-cell) MVnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? Mn3LglUh|ryP NUfLVnhWTE2VTx?= M13qfWlEPTB;MD61NkDPxE1? MYCxPVk6PjJ5Mh?=
A2780R M1vZVmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NF3Te4h,PSEQvF2= MkHqSG1UVw>? MV3JR|UxRTFwNU[0JO69VQ>? NYDGTmdVOTl7OU[yO|I>
Rh1 NYjLepFzT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MnfaglUh|ryP Mmn4SG1UVw>? MkDqTWM2OD1yLkCyO{DPxE1? NFnYTnkyQTl7NkK3Ni=>
Kasumi-1 (acute myeloid) NVu5eoM{T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NVPvTIJ6hjVizszN MlnXSG1UVw>? NVXDNIY2UUN3ME2wMlE3KM7:TR?= NU\0SZNqOTl7OU[yO|I>
sk-ov-3 M3XWfWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MXz+OUDPxE1? MoP6SG1UVw>? MnXZTWM2OD13LkGg{txO M33ZcVE6QTl4Mkey
ME NHTrTmtIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MUH+OUDPxE1? M2HKemROW09? NHOxZVBKSzVyPUCuNFE2KM7:TR?= NGq2N2cyQTl7NkK3Ni=>
L1210 (Murine lymphocytic) MVHHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NEX1VnR,PSEQvF2= MoW4SG1UVw>? NWraOFVUUUN3ME2yMlM6KM7:TR?= M3nLXFE6QTl4Mkey
sw-626 NF;NV2hIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M3ziVJ42KM7:TR?= NGLNR5JFVVOR MUTJR|UxRTJwM{C2JO69VQ>? NWXUem1jOTl7OU[yO|I>
CTR NVezeIh3T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MYj+OUDPxE1? NXrV[I9ITE2VTx?= MoTKTWM2OD1yLkK1N{DPxE1? MWmxPVk6PjJ5Mh?=
ML2 (Myelomonocytic) NEDYXWFIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MXL+OUDPxE1? MkLSSG1UVw>? M1TXZWlEPTB;MD6wPUDPxE1? M1XnPFE6QTl4Mkey
ovcar-3 NH7VeIdIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NVq4dIxshjVizszN M37ISGROW09? MkWxTWM2OD13IN88US=> M2Tne|E6QTl4Mkey
Rh36 NV;L[nhRT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NWHXeplDhjVizszN M2DHSWROW09? MkPyTWM2OD1zLkSzNkDPxE1? NVjCe4djOTl7OU[yO|I>
MOLM-13 (acute myeloid) MmHMS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NFvkfWt,PSEQvF2= M1;JRWROW09? MoqwTWM2OD1yLkSyJO69VQ>? NHTIUGwyQTl7NkK3Ni=>
ovcar-4 MYTHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MnLFglUh|ryP M37CZ2ROW09? NHjaUJhKSzVyPUGg{txO MXGxPVk6PjJ5Mh?=
Rh41 M1fLSWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NXrjRXhlhjVizszN MXjEUXNQ NVXTcFRtUUN3ME2wMlAxPSEQvF2= MWWxPVk6PjJ5Mh?=
Mutz 2 (acute myeloid) NFzkZYZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MVf+OUDPxE1? NFXKZmpFVVOR M{m1RmlEPTB;MT6xOUDPxE1? NETqcZAyQTl7NkK3Ni=>
ovcar-5 MYDHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MnH3glUh|ryP NHPadmpFVVOR M1fZZ2lEPTB;MD6wOUDPxE1? NVXnZY9VOTl7OU[yO|I>
RD1 MYXHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M{PnOp42KM7:TR?= MX7EUXNQ NFW1SYhKSzVyPUCuNFY5KM7:TR?= NV23[phpOTl7OU[yO|I>
OCI-AML 2 (acute myeloid) MlTIS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MmnnglUh|ryP MmXuSG1UVw>? NEXzSJhKSzVyPUOuN|Mh|ryP MnXONVk6QTZ{N{K=
786-O M4n4SWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MoTIglUh|ryP M4Wxe2ROW09? NHnSdI1KSzVyPUGuOlQ4KM7:TR?= NWn4RlFjOTl7OU[yO|I>
A673 NE\nWIZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NGDqXpJ,PSEQvF2= M{H0WWROW09? M3XiVmlEPTB;MD60NFgh|ryP M1fae|E6QTl4Mkey
TALL-1 (T-cell) MX\Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NFXUUlF,PSEQvF2= MmCwSG1UVw>? M3PuXmlEPTB;MT6yPEDPxE1? M1fIUFE6QTl4Mkey
151-B M{HxVWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M{XYOp42KM7:TR?= M4PFeWROW09? MUfJR|UxRTJwNkeg{txO M12zRlE6QTl4Mkey
PFSK-1 MXnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NUDzRWZShjVizszN MVvEUXNQ NIPTcm1KSzVyPUCuNVMzKM7:TR?= MXixPVk6PjJ5Mh?=
THP-1 NIXhe25Iem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MoXaglUh|ryP M{nWOGROW09? NVjURYI5UUN3ME22MlU5KM7:TR?= Mn;iNVk6QTZ{N{K=
HEK293 NWLJeIUzT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M2Xacp42KM7:TR?= NIDjNHVFVVOR NWXnbWpwUUN3ME2wMlkyPSEQvF2= NHj2XokyQTl7NkK3Ni=>
DAOY NHrHSWJIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MoTjglUh|ryP MmDlSG1UVw>? MmnWTWM2OD1zLkm3PUDPxE1? MX2xPVk6PjJ5Mh?=
SET2 MWTHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M4TOZ542KM7:TR?= MoX5SG1UVw>? NW\zT|NlUUN3ME2wMlI6QCEQvF2= NXzBdHRyOTl7OU[yO|I>
HTB-46 NELyb3dIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NHLFVWZ,PSEQvF2= M2CwZ2ROW09? M1jWSmlEPTB;NT6yOUDPxE1? Ml3xNVk6QTZ{N{K=
SK-NAS Mo\kS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? M2n1OJ42KM7:TR?= M1;teWROW09? NF\BfGtKSzVyPUCuOFk4KM7:TR?= MmPSNVk6QTZ{N{K=
CTLL2 NF3zPGhIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M3X2d542KM7:TR?= NXnnOY1yTE2VTx?= MXjJR|UxRjFwMECg{txO MUKxPVk6PjJ5Mh?=
HTB-47 NFrpfZJIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M17FWZ42KM7:TR?= NI\r[oVFVVOR MlWwTWM2OD1{LkC1OkDPxE1? NVX5UYg1OTl7OU[yO|I>
LAN-1 MVTHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M{fCR542KM7:TR?= NGnNfJdFVVOR Mny4TWM2OD1yLkC0JO69VQ>? NGDVUmgyQTl7NkK3Ni=>
ST486 MUfHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NIHaeJF,PSEQvF2= NIS3enZFVVOR M3vibmlEPTB;MT6xPUDPxE1? M{DvOlE6QTl4Mkey
HS766T MontS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NHjyVmp,PSEQvF2= M2nlPGROW09? MmXLTWM2OD1{LkCwNUDPxE1? MkSxNVk6QTZ{N{K=
IMR-32 MmjCS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MYf+OUDPxE1? Mme1SG1UVw>? MUTJR|UxRTBwMk[xJO69VQ>? MoHaNVk6QTZ{N{K=
Daudi (Burkitt's) M2rrcmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M1XCRp42KM7:TR?= Ml\wSG1UVw>? MnO0TWM2OD1{Lk[zO{DPxE1? M2H6blE6QTl4Mkey
Aspc-1 M4HU[Gdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NXmxeZlxhjVizszN M3\MeWROW09? MnLITWM2OD1yLkO3PUDPxE1? NXrueo02OTl7OU[yO|I>
SK-NSH NHnJdpRIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MUL+OUDPxE1? NHjadlBFVVOR NF3Td3BKSzVyPUCuNVM6KM7:TR?= NVW5R5Q5OTl7OU[yO|I>
MEC-1 (Chronic B cell) NFv3RmdIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M{X4Zp42KM7:TR?= NVfFNHlkTE2VTx?= MV\JR|UxRTJwNkO3JO69VQ>? M3zlOlE6QTl4Mkey
Capan-2 MoTWS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MXT+OUDPxE1? M1\zdWROW09? M{XBXmlEPTB;MT63O|Qh|ryP MmrxNVk6QTZ{N{K=
SHSY5Y MoL4S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NXLPWYtbhjVizszN Ml\zSG1UVw>? NEDDWHBKSzVyPUCuNVA3KM7:TR?= Mlf5NVk6QTZ{N{K=
U937 (Histioocytic) MnPxS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MlfGglUh|ryP Mn3mSG1UVw>? M2WzcWlEPTB-NT6wNEDPxE1? MlHMNVk6QTZ{N{K=
Bxpc-1 NGHudmhIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NVq4XIJRhjVizszN NY\3d3NKTE2VTx?= Mk\tTWM2OD1zLkmyOEDPxE1? NGLrTYQyQTl7NkK3Ni=>
Bxpc-3 MVnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NH[5RlR,PSEQvF2= NY\URpFPTE2VTx?= M1;2XWlEPTB-NT6wNEDPxE1? Mn7PNVk6QTZ{N{K=
HTB-92 MnzJS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MnTjglUh|ryP NYrQUmk6TE2VTx?= NITtNWlKSzVyPUGuNFIh|ryP MmriNVk6QTZ{N{K=
OCI-LY10 (B-cell) NIfBepFIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NYLuemlThjVizszN NVXRTW5YTE2VTx?= MkHoTWM2OD1yLkS1JO69VQ>? NVLRSVJZOTl7OU[yO|I>
PANC-1 NH\OOIZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MUj+OUDPxE1? MYjEUXNQ MWHJR|UxRjVwMECg{txO M4LCelE6QTl4Mkey
To184.T MUjHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MnTrglUh|ryP NWXubWh3TE2VTx?= MkjMTWM2OD1yLkS2PUDPxE1? MnnONVk6QTZ{N{K=
OCI-LY19 (B-cell) M4TwS2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NXLKRW1WhjVizszN M3vpUGROW09? NYPjRXIxUUN3ME2wMlQh|ryP MV6xPVk6PjJ5Mh?=
PANC-1 BM NFXvd5lIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MYX+OUDPxE1? MVfEUXNQ M4HUemlEPTB-NT6wNEDPxE1? NY\0Rng3OTl7OU[yO|I>
SA-4 MV\Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M4nRUZ42KM7:TR?= MUXEUXNQ MXzJR|UxRTFwM{CxJO69VQ>? Mm\aNVk6QTZ{N{K=
RPMI 8226 NFXKS|VIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NYXxTo9nhjVizszN NUTJR2d2TE2VTx?= M3fCV2lEPTB;MT6yPVMh|ryP MYWxPVk6PjJ5Mh?=
HPAF-II M4rkWGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M{HTU542KM7:TR?= NGPUdpVFVVOR MnziTWM2OD1yLk[0OEDPxE1? MWqxPVk6PjJ5Mh?=
SHP-77 NGXUVplIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NI\RS4V,PSEQvF2= NWHJeYFiTE2VTx?= NHzXTIJKSzVyPUGuPFg5KM7:TR?= MUKxPVk6PjJ5Mh?=
U266 B1 NVTSfoJKT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M4jZWJ42KM7:TR?= NFnOeVNFVVOR NFuwR2FKSzVyPUGuOlY6KM7:TR?= Mn\QNVk6QTZ{N{K=
Hs700t MWfHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M3XjRp42KM7:TR?= M1jCeWROW09? M1fsbmlEPTB;MD6yN|Eh|ryP MXmxPVk6PjJ5Mh?=
NCI-446 NFP5fIxIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MWf+OUDPxE1? Ml7HSG1UVw>? NFy5NG1KSzVyPUGuNVU1KM7:TR?= M3HwSVE6QTl4Mkey
H929 NUToWHVbT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NV;0VI5lhjVizszN MXTEUXNQ NVezWWQyUUN3ME2wMlAyPCEQvF2= NFywWXgyQTl7NkK3Ni=>
PL45 NVTUeWZJT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M1XIfZ42KM7:TR?= M37JOGROW09? MnnaTWM2OD1{LkK1OUDPxE1? M13NflE6QTl4Mkey
NCI-H383 M4nLVGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MVn+OUDPxE1? MYnEUXNQ NVLRZ2xMUUN3ME61MlAxKM7:TR?= MnnKNVk6QTZ{N{K=
JJN3 MnfzS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MUL+OUDPxE1? NY\oTopFTE2VTx?= M3zTN2lEPTB;Mj60N|Mh|ryP M1TBSlE6QTl4Mkey
SU.86.86 M13UbGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MmXGglUh|ryP M{\XRWROW09? NWfQSIpRUUN3ME2yMlY4OiEQvF2= M4\MRVE6QTl4Mkey
H1299 M3W1Umdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MnHWglUh|ryP MV3EUXNQ MVPJR|UxRjVwMECg{txO M{m2W|E6QTl4Mkey
MDA-MB-468 M4DyOGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MUn+OUDPxE1? MmPqSG1UVw>? M1T4[WlEPTB;MD61NFQh|ryP NVm3XXhYOTl7OU[yO|I>
SW1990 MUXHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M2PXXJ42KM7:TR?= MWHEUXNQ NFTX[odKSzVyPUCuPFI3KM7:TR?= NIm2cGkyQTl7NkK3Ni=>
Calu-6 M1rYdWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NGCwdmd,PSEQvF2= NVTOO|JwTE2VTx?= NUTLXFloUUN3ME61MlAxKM7:TR?= MlfENVk6QTZ{N{K=
MDA-MB-231 NV\4dFU5T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NVzId3VIhjVizszN MVXEUXNQ NIniZpBKSzVyPUGuOlQ5KM7:TR?= NXnVXIlwOTl7OU[yO|I>
SW-684 M2LmRmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M2P4d542KM7:TR?= NXLuT3dTTE2VTx?= NUPIUFZzUUN3ME61MlAxKM7:TR?= NGP4R40yQTl7NkK3Ni=>
H209 MkHxS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NXLFOmlKhjVizszN MYPEUXNQ NX2yTW8zUUN3ME2xMlE6OyEQvF2= M2fVelE6QTl4Mkey
MDA-MB-231T M3S2[2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M1HmSJ42KM7:TR?= NVnRSplrTE2VTx?= MYfJR|UxRjVwMECg{txO MXSxPVk6PjJ5Mh?=
HT1080/S NVXTN4l1T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NHj6UWx,PSEQvF2= NX3obWp{TE2VTx?= NV7JRpVFUUN3ME2wMlU{OSEQvF2= NFPweoEyQTl7NkK3Ni=>
H526 0.044 MkfpS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? Mn7IglUh|ryP MXzEUXNQ NFzhdFVKSzVyPUCuNFQ1KM7:TR?= MUWxPVk6PjJ5Mh?=
DU4475 2.431 NFvlRllIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NH7XU2d,PSEQvF2= NIH0SWpFVVOR M{LhfmlEPTB;Mj60N|Eh|ryP NH;WdpkyQTl7NkK3Ni=>
HCT116 MWHHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NHnUUmZ,PSEQvF2= M1\4S2ROW09? NHznPZFKSzVyPUCuPFUzKM7:TR?= MWOxPVk6PjJ5Mh?=
M109 MoT0S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MoO4glUh|ryP NX;0dXNqTE2VTx?= M2rVSWlEPTB;MT6wOVUh|ryP M2rvOVE6QTl4Mkey
BT549 MYLHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MnewglUh|ryP NX;ZbWNOTE2VTx?= MX3JR|UxRTFwNkS1JO69VQ>? MVOxPVk6PjJ5Mh?=
HCT116/VM46 M163Z2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NELjfGN,PSEQvF2= MVTEUXNQ NHu0N3VKSzVyPUGuO|AzKM7:TR?= MnLZNVk6QTZ{N{K=
H460 NYPQXnFjT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MV\+OUDPxE1? MXvEUXNQ MoPHTWM2OD1yLke5OUDPxE1? MUCxPVk6PjJ5Mh?=
MCF-7 MV;Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MmDLglUh|ryP NYWyXWVyTE2VTx?= NYPUZZh4UUN3ME2wMlAyPiEQvF2= MV2xPVk6PjJ5Mh?=
GEO M3XwZmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 Mor6glUh|ryP MmPxSG1UVw>? Mn7nTWM2OD1yLkO1OkDPxE1? NHj6V4QyQTl7NkK3Ni=>
H441 0.646 NY\RWYNqT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NU\S[nA1hjVizszN MX\EUXNQ M3f6WGlEPTB;MD62OFYh|ryP MmTQNVk6QTZ{N{K=
MCF-7-807R M1TuTmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NFrIXo5,PSEQvF2= MlTKSG1UVw>? MULJR|UxRTBwNEmg{txO MmC5NVk6QTZ{N{K=
Colo205 MkXZS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NITJSWJ,PSEQvF2= M{jlfWROW09? MY\JR|UxRTBwMUC0JO69VQ>? MYWxPVk6PjJ5Mh?=
H292 NVvaOHZMT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NVjaNZUzhjVizszN NX7oTXRlTE2VTx?= MUXJR|UxRTBwN{i4JO69VQ>? NUXQbWdJOTl7OU[yO|I>
BT474 (S) MX;Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NYmxXXhwhjVizszN MUDEUXNQ NWTpUIFCUUN3ME2yMlQxOyEQvF2= NXTufox1OTl7OU[yO|I>
HT-29 NW\IcnFMT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NFvtPJJ,PSEQvF2= NWHQWmxOTE2VTx?= NGLNdHZKSzVyPUKuNVA{KM7:TR?= MV[xPVk6PjJ5Mh?=
A549 NIP1dItIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NVvhfJdzhjVizszN MWnEUXNQ NY\xSVBEUUN3ME2wMlY4PSEQvF2= NUOyPGlJOTl7OU[yO|I>
BT474-M1 MXTHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M3THTZ42KM7:TR?= MU\EUXNQ M2\2T2lEPTB;Mj6zOlUh|ryP MnLvNVk6QTZ{N{K=
SW480 MmjzS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NHvPZWF,PSEQvF2= MlXJSG1UVw>? NGiw[IRKSzVyPkWuNFAh|ryP NITleYcyQTl7NkK3Ni=>
L2987 MXTHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NWH3SHFqhjVizszN Mo\HSG1UVw>? NH6wPJpKSzVyPUCuOFQzKM7:TR?= NECwW|gyQTl7NkK3Ni=>
AU565 MkDUS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MUn+OUDPxE1? MUTEUXNQ MlfrTWM2OD12Lkm3JO69VQ>? MVSxPVk6PjJ5Mh?=
SW403 MXnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MVT+OUDPxE1? NHvtVIZFVVOR NVzJWop{UUN3ME2wMlIzKM7:TR?= Ml[xNVk6QTZ{N{K=
H1437 MlG4S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MVv+OUDPxE1? Mo\oSG1UVw>? NIXiTGNKSzVyPUCuOVI{KM7:TR?= NX\VcI9EOTl7OU[yO|I>
BT-20 MlzaS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NVjVT|hphjVizszN MmHsSG1UVw>? MVnJR|UxRTNwNU[yJO69VQ>? MkjTNVk6QTZ{N{K=
Colo320HSR MmPLS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? M3SwZZ42KM7:TR?= MWLEUXNQ NUXi[lVWUUN3ME2wMlAyOSEQvF2= NIjxWIgyQTl7NkK3Ni=>
H2087 M2PIZ2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M1jnSJ42KM7:TR?= MWnEUXNQ M2TRcmlEPTB-MT6wNEDPxE1? MorZNVk6QTZ{N{K=
HCC1419 NYS3cYZ{T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MmHRglUh|ryP MlTUSG1UVw>? M1;qTWlEPTB;Mj61NVch|ryP M3jyOVE6QTl4Mkey
WiDr M4n6dGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NYHOboJ{hjVizszN MYTEUXNQ MXTJR|UxRTBwMEe2JO69VQ>? M124bVE6QTl4Mkey
H661 0.573 NHy3dHJIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NWraO3pyhjVizszN M2G4dmROW09? MoLnTWM2OD1yLkW3N{DPxE1? NYHrW4Z2OTl7OU[yO|I>
HCC-38 MXjHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MVL+OUDPxE1? NGT5dYJFVVOR NUjpNmE2UUN3ME61MlAxKM7:TR?= MnLnNVk6QTZ{N{K=
LS174T M3KwSWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NVy0V4VihjVizszN NGqxb3FFVVOR NYLWZWtkUUN3ME2wMlU{PSEQvF2= NXHQO|VuOTl7OU[yO|I>
H211 Ml;RS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? M{Xpep42KM7:TR?= M{PVTmROW09? NETrTIRKSzVyPUCuO|M{KM7:TR?= MUixPVk6PjJ5Mh?=
HCC70 MWrHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NGS2[4t,PSEQvF2= NF;HcHlFVVOR M1S2RWlEPTB;MT61OUDPxE1? MUKxPVk6PjJ5Mh?=
SW116 M2r4c2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M1P1OJ42KM7:TR?= NF31Z5pFVVOR MWPJR|UxRTBwME[3JO69VQ>? M{\oTFE6QTl4Mkey
H513 MYLHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NIjMfmZ,PSEQvF2= NXXBUXY4TE2VTx?= M{LYSmlEPTB;ND60OFgh|ryP M{XsV|E6QTl4Mkey
MDA-MB-157 NEPPRppIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M{\N[Z42KM7:TR?= NVzxWIc5TE2VTx?= NUjKNIJwUUN3ME2wMlA{PiEQvF2= NVizelRMOTl7OU[yO|I>
H2052 MoTBS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MkO0glUh|ryP NIrETGZFVVOR MVjJR|UxRTFwMEWg{txO M{nDVlE6QTl4Mkey
MDA-MB-415 NHjEPJZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MUj+OUDPxE1? NVWwW4lmTE2VTx?= MnywTWM2OD53LkCwJO69VQ>? MVmxPVk6PjJ5Mh?=
DLD-1 M2rnNWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NIXuPXV,PSEQvF2= M{nZd2ROW09? MkXkTWM2OD1yLkmwPUDPxE1? MUGxPVk6PjJ5Mh?=
H2595 NYrzZlJET3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MXL+OUDPxE1? MWLEUXNQ MnzVTWM2OD12LkS3OUDPxE1? M3TVNlE6QTl4Mkey
MDA-MB-435S NH7wZ3RIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M3LPOZ42KM7:TR?= NYPTc5Z5TE2VTx?= MlnJTWM2OD1zLki2PUDPxE1? MV6xPVk6PjJ5Mh?=
HCT15 NHTWc3hIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MkjVglUh|ryP MWDEUXNQ M2joUmlEPTB-MT6wNEDPxE1? MVGxPVk6PjJ5Mh?=
SK-Hep1 Mor2S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MYn+OUDPxE1? MoT4SG1UVw>? M1LSVmlEPTB;MD6xOFYh|ryP MWexPVk6PjJ5Mh?=
MDA-MB-436 MoC5S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MnK3glUh|ryP NFT5ZWNFVVOR NH7jbmFKSzVyPUWuOVAzKM7:TR?= NEXiXlMyQTl7NkK3Ni=>
KM12C MkHES5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MluzglUh|ryP NV7DVodjTE2VTx?= NWXyeolqUUN3ME2wMlA2PCEQvF2= Mo\QNVk6QTZ{N{K=
HEPG2 NF;ZS2JIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M1jJPJ42KM7:TR?= M{DqPGROW09? MX3JR|UxRTBwMEK1JO69VQ>? NH[5epQyQTl7NkK3Ni=>
MDA-MB-453 NXXG[Y1KT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M2KzSJ42KM7:TR?= MorBSG1UVw>? MVjJR|UxRTFwOE[5JO69VQ>? M1vNSFE6QTl4Mkey
KM12SM NVPQXnA{T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NYfDboQ6hjVizszN NX;tS5VVTE2VTx?= M3qyT2lEPTB;MD6wOVkh|ryP MVixPVk6PjJ5Mh?=
1483 MmTQS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? Mm\pglUh|ryP MYTEUXNQ MWrJR|UxRTJwMUmg{txO NHvJUYkyQTl7NkK3Ni=>
Hs578t MmfIS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MXf+OUDPxE1? M33UW2ROW09? MoTSTWM2OD1zLkK4O{DPxE1? NYHDO|REOTl7OU[yO|I>
LS180 MWXHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M4DVZp42KM7:TR?= MYHEUXNQ MXvJR|UxRTBwNkm2JO69VQ>? MYKxPVk6PjJ5Mh?=
FaDu M17IT2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MkT5glUh|ryP MmrMSG1UVw>? M2DGVmlEPTB;MT6yO{DPxE1? MUWxPVk6PjJ5Mh?=
ZR-75-1 NYXaV286T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MUP+OUDPxE1? NHP5XpRFVVOR M2LzVWlEPTB;Mj6wPFQh|ryP NXTUTHRlOTl7OU[yO|I>
LS513 MmDLS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MnvTglUh|ryP M3nBUGROW09? NH[0e3lKSzVyPUCuNVM2KM7:TR?= M4fsWVE6QTl4Mkey
Detroit.562 MmixS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MXr+OUDPxE1? NXy1b44zTE2VTx?= NVX0c3dVUUN3ME2xMlE1KM7:TR?= MkS5NVk6QTZ{N{K=
ZR-75-30 NELnXmVIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NULMdYQ4hjVizszN NVnGVGM6TE2VTx?= NHLNPWZKSzVyPkWuNFAh|ryP MXKxPVk6PjJ5Mh?=
RKO-PM MnrwS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NGP1TW5,PSEQvF2= NYHmPWxCTE2VTx?= NXHI[YZWUUN3ME2wMlI{OiEQvF2= NFHCU2cyQTl7NkK3Ni=>
Cal.27 M1;yWmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NVHoUIlWhjVizszN NWnGR|JJTE2VTx?= MlLxTWM2OD1{IN88US=> NEXkdYkyQTl7NkK3Ni=>
KPL4 M4H4dWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MYH+OUDPxE1? MUfEUXNQ NFL1UXFKSzVyPUGuNlUzKM7:TR?= NX\uS286OTl7OU[yO|I>
PKO-RM13 M13tWWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MoTsglUh|ryP NHHyTZFFVVOR MULJR|UxRTBwNEK1JO69VQ>? NX;1eHp{OTl7OU[yO|I>
HS.53.T NY\VcXdCT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MXv+OUDPxE1? MoL5SG1UVw>? MV7JR|UxRTBwN{mg{txO NInST4UyQTl7NkK3Ni=>
EMT6 M2fpdmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MUP+OUDPxE1? MXXEUXNQ NVzEcpdXUUN3ME2wMlgxPiEQvF2= NFjBUJgyQTl7NkK3Ni=>
SNU-C1 M1SxWGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MXP+OUDPxE1? M{ewfmROW09? MUXJR|UxRTBwMEC3JO69VQ>? NF7DbnQyQTl7NkK3Ni=>
SQCCY1 NInmOYtIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NWrLVo5KhjVizszN NXj6eXd3TE2VTx?= M2f4fGlEPTB;MD63PUDPxE1? NYDJOYl6OTl7OU[yO|I>
SW480 MU\Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NYi5WWN3hjVizszN NGrKUVVFVVOR NU\XTWhjUUN3ME2wMlA{PyEQvF2= MW[xPVk6PjJ5Mh?=
SCC9 M3nEfmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MWH+OUDPxE1? M3fYOGROW09? M1HDPWlEPTB;MD63OUDPxE1? M4DPblE6QTl4Mkey
SK-LMS-1 MWjHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NGrCU4p,PSEQvF2= NW\mbW03TE2VTx?= NXXYW2hIUUN3ME2wMlY5PyEQvF2= M1;TVFE6QTl4Mkey
SCC25 M3e5OGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M1LvO542KM7:TR?= MVXEUXNQ M{XUSmlEPTB;MD62PEDPxE1? M37zT|E6QTl4Mkey
U87 M3\BZWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M2f2cJ42KM7:TR?= NI\VOpBFVVOR MVrJR|UxRTBwOUWg{txO M3jsPFE6QTl4Mkey
SCC15 MXfHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MXT+OUDPxE1? NF\ScVhFVVOR MYPJR|UxRTBwNkeg{txO Mn\BNVk6QTZ{N{K=
T98G MoGxS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MnnmglUh|ryP MUnEUXNQ NUDoSJZLUUN3ME2xMlIyQCEQvF2= NUOzWnZUOTl7OU[yO|I>
SCC4 MUTHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M3ezfp42KM7:TR?= M33q[mROW09? MoThTWM2OD1yLk[zJO69VQ>? NU\tb3c{OTl7OU[yO|I>
U118 MWHHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M2fHSZ42KM7:TR?= M{LESmROW09? NGLFdJhKSzVyPUGuOlE5KM7:TR?= NX7LVWtDOTl7OU[yO|I>
TU167 NFHHbZZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MVn+OUDPxE1? NIS4cnhFVVOR MnK5TWM2OD12LkWyJO69VQ>? NX7FeWp6OTl7OU[yO|I>
NCI-H727 MkfjS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? M2jj[Z4yOOLCit88US=> M{n0TWROW09? MkDHTWM2OD12Mkigcm0> MVqyNFM5PTd2Nx?=
NCI-H720 MoXrS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NHLwemd,OTEkgJtOwG0> NHLaUFdFVVOR NHTUSGhKSzVyPUKuPEDPxE1? NGXvdFUzODN6NUe0Oy=>
NCI-H835 NEOweI5Iem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MVv+NVDjiIsQvF2= NFm4TIRFVVOR MVXJR|UxRTFizszN NEflUI4zODN6NUe0Oy=>
NCI-H727 MnjNT4lv[XOnIHHzd4F6 M{\IUp4yOOLCit88US=> NU\q[ZFpTE2VTx?= MWfpcohq[mm2czDjc45{fGm2dYTpeoUhUUeIMWKgZZV1d3Cqb4PwbI9zgWyjdHnvci=> MWiyNFM5PTd2Nx?=
RD MUnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MUj+NVDjiIsQvF2= M4fqfWlEPTB;MT6xNkDDvU1? M1[5O|IyOjl6N{S1
Rh41 MX;Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M{[5dJ4yOOLCit88US=> Mlv0TWM2OD1yLkC3JOK2VQ>? M3rNT|IyOjl6N{S1
Rh18 MoSyS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MlvSglEx6oDMzszN MknQTWM2OD12Lkm2JOK2VQ>? MW[yNVI6QDd2NR?=
Rh30 MkXmS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MVj+NVDjiIsQvF2= M2nYPWlEPTB;MD6xPUDDvU1? MW[yNVI6QDd2NR?=
BT-12 NVnBV2VlT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M4j6PZ4yOOLCit88US=> MWTJR|UxRTBwN{igxtVO NGTjOJQzOTJ7OEe0OS=>
CHLA-266 M3rke2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MorwglEx6oDMzszN M3Hhe2lEPTB;MD64PUDDvU1? NFnydnAzOTJ7OEe0OS=>
TC-71 NYHF[5NxT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MlfuglEx6oDMzszN M3q0ZWlEPTB;MD6xNUDDvU1? NWTSOllqOjF{OUi3OFU>
CHLA-9 Mn;VS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MlG0glEx6oDMzszN MXHJR|UxRTBwMUKgxtVO NXLTRWZQOjF{OUi3OFU>
CHLA-10 NE\lbYNIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NHG0WpV,OTEkgJtOwG0> M33MN2lEPTB;MD62NkDDvU1? NFHw[pgzOTJ7OEe0OS=>
CHLA-258 Ml7kS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NVTkSIRGhjFy4pEK{txO NG\GbXpKSzVyPUCuNlchyrWP NX[4WXZJOjF{OUi3OFU>
GBM2 NXHwdlFrT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M{DwNZ4yOOLCit88US=> MYXJR|UxRTFwNEegxtVO MlfPNlEzQTh5NEW=
NB-1643 NUPldGE6T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MW\+NVDjiIsQvF2= NYj6RlhjUUN3ME2wMlEzKML3TR?= MV:yNVI6QDd2NR?=
NB-EBc1 MkfXS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MYH+NVDjiIsQvF2= NHi2VJZKSzVyPUCuN|UhyrWP NYn6U2ZbOjF{OUi3OFU>
CHLA-90 MWHHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MmLnglEx6oDMzszN NEDBUZZKSzVyPUCuO|chyrWP NX\QOHRrOjF{OUi3OFU>
CHLA-136 MULHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NFjD[Id,OTEkgJtOwG0> NF[5PW5KSzVyPUCuOVIhyrWP NV7IZXdGOjF{OUi3OFU>
NALM-6 NEjl[VBIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NXWybYJ5hjFy4pEK{txO NIWweFdKSzVyPUCuOFkhyrWP NEjhT40zOTJ7OEe0OS=>
COG-LL-317 M4TaU2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NWPwbnpDhjFy4pEK{txO NG\3XmpKSzVyPUGuN|ghyrWP MlTCNlEzQTh5NEW=
RS4;11 MmrES5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NXfHU25whjFy4pEK{txO MoruTWM2OD1yLkO4JOK2VQ>? MljuNlEzQTh5NEW=
MOLT-4 M2fIbmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NXntfoZDhjFy4pEK{txO M{jvWmlEPTB;MD61N{DDvU1? NFTTbXIzOTJ7OEe0OS=>
CCRF-CEM M3v6NWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MXL+NVDjiIsQvF2= NHvReoFKSzVyPUGuNVMhyrWP MoD2NlEzQTh5NEW=
Kasumi-1 NF72eYJIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MXL+NVDjiIsQvF2= MojkTWM2OD1zLkKgxtVO Mn7qNlEzQTh5NEW=
Karpas-299 MlPUS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MoDSglEx6oDMzszN NEHFXoZKSzVyPUGuOlQhyrWP M4i2UVIyOjl6N{S1
Ramos-RA1 MWrHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NV;yT3dQhjFy4pEK{txO Mlq5TWM2OD1zLkOxJOK2VQ>? NW\YflZIOjF{OUi3OFU>
Rh30  MkLuSpVv[3Srb36gZZN{[Xl? MVzpcoR2[2W|IHHuJIlv[3KnYYPlJI9nKFOISzDwbI9{eGixconsZZRqd25? MkDFNlU6OjV|N{i=
Rh41 MUHGeY5kfGmxbjDhd5NigQ>? MnPObY5lfWOnczDhckBqdmO{ZXHz[UBw\iCVRlugdIhwe3Cqb4L5cIF1cW:w M1rt[lI2QTJ3M{e4
RD M4\wO2Z2dmO2aX;uJIF{e2G7 MUjpcoR2[2W|IHHuJIlv[3KnYYPlJI9nKFOISzDwbI9{eGixconsZZRqd25? MkL1NlU6OjV|N{i=
A549 NFHtb2pMcW6jc3WgZZN{[Xl? NFXFVIMxNjYkgJtOwG0> NIrRVWdFVVOR NIDMc5RqdmirYnn0d{BKT0ZvSWKvTXIh[WO2aY\heIlwdg>? NF7PNlQzPjl{OEW3PC=>
NCI-H358 MkX2T4lv[XOnIHHzd4F6 Ml3hNE426oDMzszN MlPMSG1UVw>? Mn7UbY5pcWKrdIOgTWdHNUmUL1nSJIFkfGm4YYTpc44> M3mx[lI3QTJ6NUe4
A549 MWfGeY5kfGmxbjDhd5NigQ>? NYPMO5kyOC534pEK{txO MnjMSG1UVw>? NEizU2Fk[XW|ZYOgZUBkd26ldYLy[Y51KGSnY4LlZZNmKGmwIIDoc5NxcG:{eXzheIVlKEGNVDDhcoQhTVKN NEP2fXIzPjl{OEW3PC=>
NCI-H358 NVTnXpkzTnWwY4Tpc44h[XO|YYm= NYnpSGQ2OC534pEK{txO MnO3SG1UVw>? MkPWZ4F2e2W|IHGgZ49v[3W{cnXueEBl\WO{ZXHz[UBqdiCyaH;zdIhwenmuYYTl[EBCU1RiYX7kJGVTUw>? NF65WnEzPjl{OEW3PC=>
A549 MkDsS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? M1rrWZ4yOOLCit88US=> MkjNSG1UVw>? NEnCOIpKSzVyPUCuO|Yh|ryP M2PM[lI3QTJ6NUe4
NCI-H358 NVHme5JkT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NU\2eHNChjFy4pEK{txO NUT5ZlJsTE2VTx?= M3zJcWlEPTB;MT6wPUDPxE1? NILPPZEzPjl{OEW3PC=>
A549 M1n1SGFxd3C2b4Ppd{Bie3OjeR?= NHjpXoExNjYkgJtOwG0> NUe2OoVzTE2VTx?= NX\1NotTcW6mdXPld{BCeG:ydH;zbZM> M2jBUFI3QTJ6NUe4
NCI-H358 MX\BdI9xfG:|aYOgZZN{[Xl? MmjGNE426oDMzszN MWPEUXNQ NUSxZVQzcW6mdXPld{BCeG:ydH;zbZM> MlX4NlY6Ojh3N{i=
A549 NXXyeolSTnWwY4Tpc44h[XO|YYm= MnvVNE426oDMzszN M{TiN2ROW09? NHT3WoZz\WS3Y3XzJJdwfW6mIHPsc5N2emV? NUTkVm5sOjZ7Mki1O|g>
NCI-H358 M1zZV2Z2dmO2aX;uJIF{e2G7 M4e0SVAvPeLCit88US=> M17MTmROW09? M3P2c5Jm\HWlZYOge492dmRiY3zvd5Vz\Q>? NITUOmwzPjl{OEW3PC=>

... Click to View More Cell Line Experimental Data

In vivo BMS-754807 (12.5mg/kg, orally) inhibits IGF-1R phosphorylation in tumor and serum in IGF-1R-Sal tumor–bearing nude mice. BMS-754807 inhibits tumor growth in a selected group of epithelial (IGF-1R-Sal, GEO, and Colo205), hematopoietic (JJN3), and mesenchymal (RD1 and Rh41) xenograft tumor models with TGI ranging from 53% to 115%. [1] BMS-754807 (6.25 mg/kg) achieves complete tumor growth inhibition in the transgenic-derived IGF-Sal tumor mouse model with correlated inhibition of pIGF-1R and pAKT. The protein binding for BMS-754807 ranges from of 98.5% in mouse plasma to 95.9% in human plasma. BMS-754807 results in clearance of 113 (mL/min)/kg, 20 (mL/min)/kg, 3.5 (mL/min)/kg and 41 (mL/min)/kg. [2] BMS-754807 (25 mg/kg) significantly inhibits tumor in KT-5 (Wilms), KT-14 (rhabdoid), Rh28 (rhabdomyosarcoma), and OS-1 xenografts mice model. [3]

Protocol

Kinase Assay:[1]
+ Expand

Kinase inhibition assays:

The primary screen for BMS-754807 is an in vitro kinase assay using recombinant human IGF-1 receptor enzyme in biochemical assays using synthetic peptide KKSRGDYMTMQIG as a phosphoacceptor substrate. The selectivity profile is evaluated against multiple recombinant enzymes that are generated at BMS or purchased externally. The enzymatic assays are performed in Ubottom 384-well plates using a 30 μL reaction volume in assay buffer (100 mM Hepes pH 7.4, 10 mM MgCl2, 0.015% Brij35 and 4 mM DTT). The 60 minute reactions are initiated by combining ATP (concentration equivalent to Km ATP), 1.5 μM fluoresceinlabeled peptide substrate, enzyme and BMS-754807. The reactions are terminated with EDTA. The reaction mixtures are analyzed on the Caliper LabChip 3000 by electrophoretic separation of the fluorescent substrate and phosphorylated product. Inhibition data are calculated by comparison to enzyme-free control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. Compounds are dissolved in dimethylsulfoxide (DMSO, 10mM stock) and evaluated at eleven concentrations. IC50 values are derived by non-linear regression analysis of the dose response curves.
Cell Research:[1]
+ Expand
  • Cell lines: IGF-1R-Sal, RH41 and Geo cell lines
  • Concentrations: 365 nM
  • Incubation Time: 72 hours
  • Method: Cells are grown at their optimal density in RPMI +GlutaMax supplemented with 10% heat-inactivated fetal bovine serum (FBS), 10 mM Hepes, penicillin, and streptomycin. Cell proliferation is evaluated by incorporation of 3H-thymidine into DNA after exposure of cells to BMS-754807 for 72 hours. Results are expressed as an IC50, which is the drug concentration required to inhibit cell proliferation by 50% compared with untreated control cells.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: IGF-1R-Sal, GEO, Colo205, JJN3, RD1 or Rh41 tumor–bearing nude mice
  • Formulation: Mixture of polyethylene glycol 400 (PEG400/water (4:1; vol/vol)
  • Dosages: 150 mg/kg
  • Administration: Orally
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 92 mg/mL (199.35 mM)
Ethanol 92 mg/mL (199.35 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 461.49
Formula

C23H24FN9O

CAS No. 1001350-96-4
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01525823 Completed Healthy Volunteers Bristol-Myers Squibb February 2012 Phase 1
NCT01225172 Completed Breast Cancer Bristol-Myers Squibb|Mayo Clinic December 2010 Phase 2
NCT00908024 Terminated Colorectal Cancer|Head and Neck Cancer|Neoplasm Metastasis Bristol-Myers Squibb October 2009 Phase 1|Phase 2
NCT00898716 Completed Neoplasms Bristol-Myers Squibb September 2009 Phase 1
NCT00788333 Completed Breast Cancer Bristol-Myers Squibb July 2009 Phase 1|Phase 2
NCT00793897 Completed Advanced Solid Tumors|Metastatic Solid Tumors Bristol-Myers Squibb April 2009 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

IGF-1R Signaling Pathway Map

IGF-1R Inhibitors with Unique Features

Related IGF-1R Products

Tags: buy BMS-754807 | BMS-754807 supplier | purchase BMS-754807 | BMS-754807 cost | BMS-754807 manufacturer | order BMS-754807 | BMS-754807 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID